公开(公告)号：US20240360095A1

公开(公告)日：2024-10-31

申请号：US18508085

申请日：2023-11-13

申请人： RHIZEN PHARMACEUTICALS AG

发明人： MEYYAPPAN MUTHUPPALANIAPPAN ,  Srikant VISWANADHA ,  Govindarajulu BABU ,  Swaroop K. VAKKALANKA

IPC分类号： C07D311/36 ,  A61K31/352 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/06 ,  C07D413/10 ,  C07D413/14 ,  C07D471/04 ,  C07D473/08 ,  C07D473/34 ,  C07D473/38 ,  C07D473/40 ,  C07D487/04

CPC分类号： C07D311/36 ,  A61K31/352 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/06 ,  C07D413/10 ,  C07D413/14 ,  C07D471/04 ,  C07D473/08 ,  C07D473/34 ,  C07D473/38 ,  C07D473/40 ,  C07D487/04 ,  Y02A50/30

摘要： The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

公开(公告)号：US12128020B2

公开(公告)日：2024-10-29

申请号：US18591994

申请日：2024-02-29

申请人： AXCESS GLOBAL SCIENCES, LLC

发明人： Ryan Lowery ,  Jacob Wilson ,  Terry Lacore

IPC分类号： A61K31/19 ,  A61K9/00 ,  A61K31/522 ,  A61P3/04 ,  A61P25/28

CPC分类号： A61K31/19 ,  A61K9/0053 ,  A61K31/522 ,  A61P3/04 ,  A61P25/28

摘要： In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof.

公开(公告)号：US20240350518A1

公开(公告)日：2024-10-24

申请号：US18574774

申请日：2022-07-26

申请人： INNOCAN PHARMA LTD

发明人： Nir AVRAM

IPC分类号： A61K31/00 ,  A61K31/522 ,  A61P17/14

CPC分类号： A61K31/658 ,  A61K31/522 ,  A61P17/14

摘要： Described herein are compositions which can be used to treat and prevent hair loss. The compositions comprise a cannabinoid, preferably cannabidiol. The compositions may comprise other ingredients that act synergistically with the cannabinoid to enhance hair growth, increase hair strength, or promote hair thickness in patients in need thereof. Further described are methods for treatment of hair loss comprising administering such compositions.

公开(公告)号：US20240342172A1

公开(公告)日：2024-10-17

申请号：US17314550

申请日：2021-05-07

申请人： VIRACTA THERAPEUTICS, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

发明人： Ronald J. Berenson ,  Douglas V. Faller

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC分类号： A61K31/506 ,  A61K9/0053 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30

摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US20240342082A1

公开(公告)日：2024-10-17

申请号：US18624704

申请日：2024-04-02

申请人： NICOVENTURES TRADING LIMITED

发明人： CHRISTOPHER KELLER ,  RONALD K. HUTCHENS ,  THOMAS H. POOLE ,  NICOLAS VON COSMOS ,  ANTHONY RICHARD GERARDI ,  CHRIS J. GRIMES ,  STEVEN LEE ALDERMAN ,  DARRELL EUGENE HOLTON, JR. ,  ROSS JAY ODEN ,  MATTHEW EVAN LAMPE ,  MICHAEL ANDREW ZAWADZKI ,  KRISTEN SPIELBAUER

IPC分类号： A61K9/00 ,  A61K31/197 ,  A61K31/198 ,  A61K31/205 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/522 ,  A61K31/7068 ,  A61K36/258 ,  A61K36/53 ,  A61K36/77 ,  A61K47/02 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K9/009 ,  A61K31/197 ,  A61K31/198 ,  A61K31/205 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/522 ,  A61K31/7068 ,  A61K36/258 ,  A61K36/53 ,  A61K36/77 ,  A61K47/02 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38

摘要： A composition configured for oral use is provided, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.

公开(公告)号：US20240342079A1

公开(公告)日：2024-10-17

申请号：US18251018

申请日：2021-11-03

申请人： Patrick FABER

发明人： Patrick FABER

IPC分类号： A61K9/00 ,  A61K31/198 ,  A61K31/405 ,  A61K31/522

CPC分类号： A61K9/0043 ,  A61K31/198 ,  A61K31/405 ,  A61K31/522

摘要： Pulverulent compositions for a nasal application containing taurine, caffeine, L-arginine and L-tryptophan, and containers and kits containing such compositions, and to uses of the compositions are discussed.

公开(公告)号：US20240307404A1

公开(公告)日：2024-09-19

申请号：US18678506

申请日：2024-05-30

申请人： ONCOCROSS Co., Ltd.

发明人： Yi-Rang KIM ,  Jin Woo CHOI

IPC分类号： A61K31/522 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06

CPC分类号： A61K31/522 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.

公开(公告)号：US20240307402A1

公开(公告)日：2024-09-19

申请号：US18431910

申请日：2024-02-02

申请人： IMPETIS BIOSCIENCES LTD.

发明人： Kasim Mookhtiar ,  Sujay Basu ,  Sreekanth Rouduri ,  Ashwin Meru

IPC分类号： A61K31/522 ,  A61K39/395

CPC分类号： A61K31/522 ,  A61K39/3955

摘要： The present disclosure discloses a pharmaceutical composition comprising compound of Formula I, Formula II, Formula III, Formula IV, and their pharmaceutically acceptable salts, analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, metabolites, and prodrugs thereof, for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by inhibition of the A2A/A2B receptor. It further discloses the use of the pharmaceutical composition of the present disclosure, for the preparation of a medicament for the treatment of a condition or disorder selected from prostate cancer, rectal cancer, renal cancer, ovarian cancer, endometrial cancer, thyroid cancer, pancreatic cancer, breast cancer, colon cancer, bladder cancer, brain cancer, glial cancer, melanoma cancer, pineal gland cancer, or lung cancer.

公开(公告)号：US12083184B2

公开(公告)日：2024-09-10

申请号：US18327658

申请日：2023-06-01

申请人： Viking Scientific, Inc.

发明人： Paul Fisher ,  Paulina Davis

IPC分类号： A61K47/69 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K9/70 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/245 ,  A61K31/522 ,  A61K31/555 ,  A61K31/606 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  A61K47/08 ,  A61K47/34 ,  A61K47/55 ,  A61K47/59 ,  A61K47/60

CPC分类号： A61K47/6903 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/14 ,  A61K9/7007 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/245 ,  A61K31/522 ,  A61K31/555 ,  A61K31/606 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  A61K47/08 ,  A61K47/34 ,  A61K47/55 ,  A61K47/59 ,  A61K47/60

摘要： Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

公开(公告)号：US12083119B2

公开(公告)日：2024-09-10

申请号：US17545217

申请日：2021-12-08

申请人： VIRACTA SUBSIDIARY, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

发明人： Ronald J. Berenson ,  Douglas V. Faller

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC分类号： A61K31/506 ,  A61K9/0053 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/4045 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K38/12 ,  A61K2300/00

摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.